Advanced Search
LI Yanping, ZHOU Yajuan, WU Yuan, LI Ying, PI Guoliang, HE Hanping, TAN Wenyong. Theoretical Analysis of Optimal Dose-fractionation of Intensity-modulated Radiotherapy in Head and Neck Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(02): 148-152. DOI: 10.3971/j.issn.1000-8578.2014.02.013
Citation: LI Yanping, ZHOU Yajuan, WU Yuan, LI Ying, PI Guoliang, HE Hanping, TAN Wenyong. Theoretical Analysis of Optimal Dose-fractionation of Intensity-modulated Radiotherapy in Head and Neck Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(02): 148-152. DOI: 10.3971/j.issn.1000-8578.2014.02.013

Theoretical Analysis of Optimal Dose-fractionation of Intensity-modulated Radiotherapy in Head and Neck Squamous Cell Carcinoma

More Information
  • Received Date: May 07, 2013
  • Revised Date: July 17, 2013
  • Objective To analyze theoretically the optimal dose-fractionation of intensity-modulated radiotherapy in head and neck squamous cell carcinoma (HNSCC). Methods The common dosefractionation of 33 division, keeping the irradiation dose of 70 Gy, biological effect dose (BED) of 84Gy10 and prolong overall treatment time was applied to simulate different dose and time treatment, respectively. The linear-quadric function was used to calculate the tumor, early response (mucosal), late response BED and the tumor log10 cell kill with different fraction number and/or dose to fi nd out the optimal fractionation. Results With 33 fractions, the fraction dose and total irradiation dose varied from 2.12-2.30 Gy and 70.0-75.9 Gy respectively. The doses of tumor, mucosal and late effect BED were 69.6Gy-78.2Gy10, 55.5-64.1Gy10, and 119.4-129.5Gy3 respectively. The tumor log10 cell kill was 10.6-11.9. While keeping the physical irradiation dose of 70 Gy or BED of 84Gy10, the fraction dose ranged from 2.20-2.80 Gy with 25-35 fractions and the total treatment day (TTD) was 32-46. The doses of tumor, early and late response BED were 67.5-82.3Gy10, 53.1-69.8Gy10, and 113.5-119.8Gy3 respectively and the tumor log10 cell kill was 10.3-12.5. Taking the tumor, early and late response BED and tumor cell log10 kill into comprehensive consideration, the regimen with 30 daily IMRT fractions can balance the tumor control and radiation-related toxicity well. For every single prolonged day, the tumor BED decreased 1.4% (0.8Gy10) and the tumor log10 cell kill did 0.1. Conclusion The optimal dose-fraction in IMRT of HNSCC is theatrically 30 daily fractions in six weeks. And the tumor BED will decrease with the prolonged overall treatment days.
  • [1]
    Lee AW,Lin JC,Ng WT.Current management of nasopharyngeal cancer[J].Semin Radiat Oncol,2012,22(3):233-44.
    [2]
    Lee AW,Ng WT,Chan YH,et al.The battle against nasopharyngeal cancer[J].Radiother Oncol,2012,104(3):272-8.
    [3]
    Fowler JF.Practical time-dose evaluations, or how to stop worrying and learn to love linear quadratics[M]. In: Levitt SH, Purdy JA,Perez CA. Technical Basis of Radiation Therapy. Berlin Heidelberg: Springer-Verlag,2012:3-50.
    [4]
    Fowler JF. 21 years of biologically effective dose[J]. Br J Radiol, 20 10,83(991):554-68.
    [5]
    Fowler JF.Is there an optimum overall time for head and neck radiotherapy? A review, with new modelling[J].Clin Oncol (R Coll Radiol),2007,19(1):8-22.
    [6]
    Drr W,Hamilton CS,Boyd T,et al.Radiation-induced changes in cellularity and proliferation in human oral mucosa[J]. Int J Radiat Oncol Biol Phys,2002,52(4):911-7.
    [7]
    Ho KF,Fowler JF,Sykes AJ,et al.IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation diffi cult[J].Acta Oncol,2009,48(3):431-9.
  • Related Articles

    [1]XU Yao, LIU Shiguo, ZHANG Chang, ZHANG Li, JIANG Shan, ZHANG Junxia, PENG Li. Clinical Significance of Detection of ZIC1 Promoter Methylation in Peripheral Blood and Cancer Tissues of Non-small Cell Lung Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2021, 48(4): 354-357. DOI: 10.3971/j.issn.1000-8578.2021.20.0911
    [2]WAN Lihui, ZHANG Na, HUANG Ying, LI Wei, WANG Liuhua, ZHENG Yuqin, SUN Zhenzhu, CAO Yuwen. Clinical Significance of JAG1 Gene Methylation in Uygur Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(11): 734-739. DOI: 10.3971/j.issn.1000-8578.2017.17.0501
    [3]KANG Yani, LAI Dengpan, ZHANG Xiaoli, CHEN Jian, ZHAO Xiaodong. CpG Islands Methylation Status in SHP1 Gene Promoter Region in Gastric Cancer Cells[J]. Cancer Research on Prevention and Treatment, 2014, 41(08): 871-875. DOI: 10.3971/j.issn.1000-8578.2014.08.003
    [4]SONG Chao, ZHANG Yun, JIN Yongtang, YU Zaicheng, XUE Shaoli. Detection and Clinical Significance of DAPK Gene Methylation in Plasma of Non-small Cell Lung Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2013, 40(08): 772-775. DOI: 10.3971/j.issn.1000-8578.2013.08.011
    [5]GUO Wei, GUO Yan-li, YANG Zhi-bin, KUANG Gang, QIAO Yi-ling, DONG Zhi-ming. Promoter Methylation of Transforming Growth Factor-beta Receptor Type 1 Gene and Expression of TGF-β1 in Gastric Cardia Adenocarcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(05): 524-527. DOI: 10.3971/j.issn.1000-8578.2011.05.011
    [6]TAN Shuang-xiang, HU Rui-cheng, XIAO Zhi-qiang, TANG Can-e, YI Hong, RUAN Lin, WANG Ning, HONG Xiu-qin. Methylation of annexin A1 Gene Promotes Lymphoid Node Metastasis in Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2010, 37(12): 1374-1379. DOI: 10.3971/j.issn.1000-8578.2010.12.011
    [7]GUO Yan-li, JIN Guo-liang, GUO Wei, KUANG Gang, YANG Zhi-bin, DONG Zhi-ming. Relationship between Promoter Methylation of Wif-1 and Protein Expression of VEGF-C/VEGF-D in Gastric Cardia Adenocarcinoma[J]. Cancer Research on Prevention and Treatment, 2010, 37(09): 1044-1047. DOI: 10.3971/j.issn.1000-8578.2010.09.018
    [8]DONG Zhi-ming, GUO Wei, HE Ming, YANG Zhi-bin, KUANG Gang, WANG Shi-jie. Expression and Methylation Status of RASSF1A Gene in Gastric Cardiac Adenocarcinoma[J]. Cancer Research on Prevention and Treatment, 2009, 36(07): 566-570. DOI: 10.3971/j.issn.1000-8578.2009.07.008
    [9]YU Zong-tao, YUAN Ya-li, ZHANG Ji-cai, GAO Qiong, WANG Yuan-yuan. Transcriptional Expression and Promoter methylation of FHIT gene in Lung Carcinoma Tissues and Cell[J]. Cancer Research on Prevention and Treatment, 2007, 34(07): 498-500. DOI: 10.3971/j.issn.1000-8578.2226
    [10]LIU Fen, YU Jie-ping, DENG Quan-jun, QI Yuan-ling, YU Hong-gang. Studying the Expression of PTEN and Its CpG Island Methylation Status in Gastric Carcinoma Cells[J]. Cancer Research on Prevention and Treatment, 2006, 33(09): 632-634. DOI: 10.3971/j.issn.1000-8578.1326

Catalog

    Article views (1490) PDF downloads (998) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return